Table 1.
Demographics of non-neoadjuvant and neoadjuvant group
| Results | Non-neoadjuvant group | Neoadjuvant group | p value | ||
|---|---|---|---|---|---|
| (n = 25) | (n = 11) | ||||
| % | (n) | % | (n) | ||
| Age (Median year) | 58 | (37 to 87) | 60 | (32 to 76) | 0.87 |
| Female | 40% | (10/25) | 46% | (5/11) | 0.76 |
| Race | 0.76 | ||||
| Chinese | 84% | (21/25) | 91% | (10/11) | |
| Malay | 12% | (3/25) | 9% | (1/11) | |
| Indian | 4% | (1/25) | 0% | (0/11) | |
| ECOG | 0.18 | ||||
| 0 | 71% | (5/7) | 100% | (7/7) | |
| 1 | 29% | (2/7) | 0% | (0/7) | |
| ≥ 2 | 0% | (0/7) | 0% | (0/7) | |
| CKIT mutation | 0.60 | ||||
| Wild type | 7% | (1/14) | 0% | (0/11) | |
| Exon 9 | 14% | (2/14) | 9% | (1/11) | |
| Exon 11 | 79% | (11/14) | 91% | (10/11) | |
| Size (Median cm) | 6.0 | (1.2 to 10.0) | 7.1 | (2.6 to 11.5) | 0.04* |
| ≤ 2 | 19% | (3/19) | 0% | (0/9) | |
| > 2–≤ 5 | 26% | (5/19) | 22% | (2/9) | |
| > 5– ≤ 10 | 58% | (11/19) | 44% | (4/9) | |
| > 10 | 0% | (0/19) | 33% | (3/9) | |
| Mitotic counts | 0.03* | ||||
| 0–5 per 50 HPF | 20% | (4/20) | 71% | (5/7) | |
| 6–10 per 50 HPF | 10% | (2/20) | 14% | (1/7) | |
| > 10 per 50 HPF | 70% | (14/20) | 14% | (1/7) | |
| NIH-Fletcher risk classification | 0.47 | ||||
| Very low/low | 11% | (2/19) | 25% | (2/8) | |
| Intermediate | 19% | (3/19) | 25% | (2/8) | |
| High | 74% | (14/19) | 50% | (4/8) | |
ECOG Eastern Cooperative Oncology Group